Stock FULC FULCRUM THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
8.01 USD +2.69% Intraday chart for Fulcrum Therapeutics, Inc. +29.40% +18.67%
Jul. 01 Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to Russell Small Cap Comp Value Index CI
Jul. 01 Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to Russell Small Cap Completeness Index CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Trending : Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal
DJ
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment
MT
Sanofi Signs License Deal for Rare Genetic Muscle Disease Drug
MT
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal
DJ
Fulcrum Therapeutics Enters into A Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
CI
Fulcrum Therapeutics, Inc. Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy in The Lancet Neurology
CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Fulcrum Therapeutics Announces Lifting of Clinical Hold on Potential Sickle-Cell Disease Treatment
MT
Fda Lifts Clinical Hold on Fulcrum Therapeutics' Ftx-6058 for Sickle Cell Disease
CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Fulcrum Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer, Effective August 7, 2023
CI
Fulcrum Therapeutics Enters Exclusive License Agreement With CAMP4 Therapeutics to Advance Rare Blood Disorder Therapy
MT
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
North American Morning Briefing : Hopes Build for -3-
DJ
Fulcrum Therapeutics Q4 Loss Narrows, Revenue Falls
MT
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FULC Stock
  4. News Fulcrum Therapeutics, Inc.
  5. Highlights